Subsequently, on July 19, 2021, Jehoshaphat Research published a report alleging that AdaptHealth's organic revenue growth had stalled, and that the Company had intentionally inflated and obscured its organic revenue growth figures. Following the release of the Jehoshaphat Report, AdaptHealth's stock price fell an additional $1.51 per share, or nearly 6% in value. The investigation seeks to determine whether AdaptHealth's officers and/or directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct and shareholder loss.